alexa Association Of Xenobiotic Metabolizing Enzymes Gene Polymorphism With Hepatocellular Carcinoma In Egyptian Patients
ISSN: 2155-9864

Journal of Blood Disorders & Transfusion
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

7th World Hematologists Congress
May 08-09, 2017 Barcelona, Spain

Manar Obada, Ashraf El-Fert, Asmaa Gomaa, Mohamed Hashim, Mohamed Kohla, Wael Abdelrazek, Om kolsoum Elhadad and Hala El-Said
National Liver Institute- Menoufia University, Egypt
Posters & Accepted Abstracts: J Blood Disord Transfus
DOI: 10.4172/2155-9864-C1-023
Background & Aim: Xenobiotics are metabolized by a large number of metabolizing enzymes, genetic polymorphism of their genes are suggested as modifiers of cancer risk. The present study aimed to investigate the association between xenobiotic metabolizing enzymes [cytochrome P450 (CYP), N-acetyl transferase 2 (NAT2) and UDP-glucuronosyltransferase (UGT)] gene polymorphism with the risk of HCC in patients with chronic HCV-induced cirrhosis. Methods: This study was performed on 354 subjects, divided into three groups, (group I: 150 hepatocellular carcinoma (HCC) patients, group II: 104 patients with HCV-related chronic liver disease (CLD) and group III: 100 apparently healthy control). The studied genes were genotyped using polymerase chain reaction-restriction fragment length polymorphism and allelic discrimination assays. Results: Genetic polymorphic patterns of NAT2 (M1 and M3), CYP2D 6*6, CYP2D 6*4 and CYP2D 6*3 showed a significant difference in HCC group compared to other groups. NAT2 M2 slow acetylator, CYP2D6*6 and CYP2D6*3 poor metabolizers and CYP2D 6*4 rapid metabolizer were associated with increased HCC risk (OR: 1.23, 4.0, 3.32 and 2.3 respectively). Conclusion: Increased risk for hepatocellular carcinoma in Egyptian patients infected with HCV may be associated with the genotypes: NAT2 (M2), CYP2D 6*6, CYP2D 6*4 and CYP2D6*3 and thus could help in tailoring individualized therapy and serve as potential target sites for chemotherapy.

Email: [email protected]

image PDF   |   image HTML

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version